Integrase drug resistance monitoring deserves attention because of the increasing number of patients being treated with integrase strand-transfer inhibitors. Therefore, we evaluated the integrase genotyping success rate at low-level viraemia (LLV, 51-1000 copies/mL) and resistance in raltegravir-failing patients.
Armenia, D., Fabeni, L., Alteri, C., Di Pinto, D., Di Carlo, D., Bertoli, A., et al. (2015). HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1865-1873 [10.1093/jac/dkv029].
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia
Svicher, V;Sarmati, L;Andreoni, M;Ceccherini-Silberstein, F;Perno, CF;Santoro, M
2015-01-01
Abstract
Integrase drug resistance monitoring deserves attention because of the increasing number of patients being treated with integrase strand-transfer inhibitors. Therefore, we evaluated the integrase genotyping success rate at low-level viraemia (LLV, 51-1000 copies/mL) and resistance in raltegravir-failing patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
2015_HIV1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even_JAC_Armenia.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
328.89 kB
Formato
Adobe PDF
|
328.89 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
